Spoken Alpha
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology develops and commercializes cancer treatments, including NERLYNX (neratinib), an oral medication for HER2-positive breast cancer approved in the U.S. and over 40 countries.
PUMA BIOTECHNOLOGY, INC is a Healthcare company operating in Biotechnology with a $477.2M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PBYI.
$ curl https://api.spokenalpha.com/v1/companies/PBYIFAQ
Spoken Alpha indexes PBYI's earnings call transcripts at https://spokenalpha.com/companies/PBYI. Each call links to attributed speakers and parsed analyst Q&A.
PUMA BIOTECHNOLOGY, INC. (PBYI) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
PUMA BIOTECHNOLOGY, INC. (PBYI) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $0.06 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $0.16 | $0.06 | +100.0% | $56.5M | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.04 | $-0.13 | +69.2% | $44.8M | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $0.26 | $0.19 | +36.8% | $75.5M | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $0.21 | $0.09 | +100.0% | $54.5M | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $0.12 | $0.08 | +50.0% | $52.4M | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $0.06 | $-0.02 | +100.0% | $46.0M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $0.43 | $0.14 | +100.0% | $59.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $0.45 | $0.38 | +18.4% | $80.5M | — | — | EODHD |
| Q2 FY2024 | 2024-07-31 | $-0.05 | $-0.10 | +50.0% | $47.1M | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.05 | $-0.15 | +66.7% | $43.8M | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $0.26 | $0.30 | -13.3% | $72.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $0.17 | $0.14 | +21.4% | $56.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $0.10 | $0.07 | +42.9% | $54.6M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $0.09 | $-0.01 | +100.0% | $52.8M | — | — | EODHD |
| Q4 FY2022 | 2023-03-01 | $-0.12 | $0.01 | -100.0% | $65.7M | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $0.05 | $0.03 | +66.7% | $57.1M | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $0.28 | $0.09 | +100.0% | $59.5M | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-0.01 | $-0.11 | +90.9% | $45.7M | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $0.10 | $-0.09 | +100.0% | $55.4M | — | — | EODHD |
Source: EODHD. PBYI reported actuals as published; sparse fields render as —.